Programme 2021
Thursday: May 6, 2021
10:00 (EST)
Day 1: Introduction & Virtual Meeting Objectives
John Gribben
10:10 -11:30
Session I: T Cell Lymphoma
Chairs: Laurence de Leval & Francine Foss
- EBV-associated lymphoproliferations:
- Pathobiology and Spectrum; Elaine Jaffe
- T-Cell lymphoproliferations; Olivier Tournilhac
- Biology clinics and management of breast implant-associated ALCLs
- Introduction to BIA-ALCL – pathology and genetics; Laurence de Leval
- experience from Australia; Miles Prince
- experience from USA; Neha Mehta-Shah
- Update and perspectives for epigenetic modifier therapy in PTCLs; Lorenzo Falchi
Roundtable discussion
11:30 - 1:00
Session II: Immunotherapy/Microenvironment
Chairs: David Maloney & Stephen Ansell
- Targeting the Immune Microenvironment; Massimo Di Nicola
- Microenvironment in FL pathogenesis and therapy; Patricia Pérez Galán
- CBT in specific lymphoma subtypes; Stephen Ansell
- ROR1 CARs and the tumour microenvironment; Fred Locke
- IMiDS in combination; Francisco J. Hernandez-Ilizaliturri
- Checkpoint Inhibitors; Scott J. Rodig
Roundtable discussion
1:00
End Day 1: Roundup of Day 1:
John Gribben, David Maloney, Laurence De Leval, Stephen Ansell, Francine Foss
Friday: May 7, 2021
10:00 - 10:10
Day 2: Introduction
John Gribben
10:10-11:20
Session III: Mantle Cell Lymphoma
Chair: Elaine Jaffe
- Introduction; Elaine Jaffe
- Keynote Speaker; Elias Campo
Roundtable Discussion: Elaine Jaffe, Elias Campo, Mark Roschewski, Stefania Pittaluga
11:20-1:15
Session IV: Novel Therapies Part I
Chairs: Laurie Sehn & Franck Morschhauser
- ADCs:
- Polatuzumab vedotin; Laurie Sehn
- ADCT–301 camidanlumab tesirine; Graham Collins
- CD20/CD3 bispecific antibodies: How to choose?
- Mosunetuzumab; Stephen Schuster
- CD20 TCB; Franck Morschhauser
- REGN1979; Rajat Bannerji
- DuoBody-CD3xCD20 (Epcoritamab); Martin Hutchings
- Oral PI3K delta (δ) inhibitors in lymphoma; Jennifer Brown
Roundtable Discussion
1:15
End Day 2: Roundup of Day 2:
John Gribben, Laurie Sehn, Franck Morschhauser, Elias Campo
Saturday: May 8, 2021
10:00 - 10:10
Day 3: Introduction
John Gribben
10:10 - 12:00
Session V: Novel Therapies Part II
Chairs: Gilles Salles & Sonali Smith
- Novel BTK inhibitors: how to choose?
- Zanubrutinib; Ian Flinn
- Acalabrutinib; Tom Witzig
- Loxo-305; Chan Cheah
- Tirabrutinib; Gilles Salles
- Ibrutinib combinations; Paolo Ghia
- SINE inhibitors: Selinexor; John Kuruvilla
- Tafasitamab (MOR208) in DLBCL; Gilles Salles
Roundtable Discussion
12:00 - 1:45
Session VI: T-cell Therapies for Lymphoma
Chairs: Cath Bollard & Jeremy Abramson
- CD19-CAR- T cells:
- Lisocabtagene maraleucel (liso-cel) in DLBCL; Jeremy Abramson
- Axicabtagene ciloleucel (axi-cel) in DLBCL; Sattva S. Neelapu
- Tisagenlecleucel in DLBCL; Elise Chong
- CD30-CAR T cells; Barbara Savoldo
- CD5 and/or 7 CAR T cells; Max Mamomkin
- Antigen-specific T cell Overview; Cath Bollard
- Third party EBV T cells; Susan Prockop
Roundtable Discussion
1:45
End Day 3: Virtual Meeting Summary & Conclusions
iwNHL Scientific Committee
